Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs

Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs

Source: 
Xconomy
snippet: 

A number of gene-editing companies have joined the public markets in recent years. Beam Therapeutics, which is developing a CRISPR-based technology intended to offer even more precise genomic edits, aims to become the latest one.

Cambridge, MA-based Beam filed its IPO paperwork with securities regulators late Friday. The company set a preliminary $100 million target for the offering. It has applied for a Nasdaq listing under the stock symbol “BEAM.”